Compare AbbVie Inc (ABBV) vs Sunrun Inc (RUN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Sunrun Inc — how do they compare? AbbVie Inc trades at $253.9 (market cap $449.91B), while Sunrun Inc trades at $11.41 (market cap $2.91B). The key difference: AbbVie Inc is far larger — about 154.6× Sunrun Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Sunrun Inc pays none. Which is the better fit depends on your goals.
| ABBV | RUN | |
|---|---|---|
Market Cap | $449.91B | $2.91B |
Sector | Health | Technology |
52-Week High | $261.07 | $21.41 |
52-Week Low | $184.85 | $9.07 |
Enterprise Value | $513.38B | $17.11B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Sunrun (RUN) trades at $12.97, up 1.81% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamental metrics with a low P/E of 6.09 and robust profitability margins, while recent news highlights the company's strategic partnership with Tesla for virtual power plants targeting AI data center demand. Cash flow trends show significant investing activity with positive net cash flow.
The outlook remains cautiously optimistic with analyst consensus at Buy (62%) and a $17.58 price target, though technical weakness and negative operating cash flow present near-term risks. The Tesla partnership offers growth potential in energy infrastructure, but execution risks and market volatility require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →
